NCT03343717: VAP

Physiotherapy on Pneumonia in Childrens

Completed NA Last updated 13 August 2020

What this trial tests

NA trial testing Rehabilitation in Pneumonia in 40 participants. Completed in 1 July 2020.

Timeline

1 January 2017

Primary endpoint
1 July 2020

1 July 2020

Quick facts

Lead sponsor	Universidade Metodista de Piracicaba
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	other
Enrollment	40
Start date	1 January 2017
Primary completion	1 July 2020
Estimated completion	1 July 2020
Sites	1 location across Brazil

Drugs / interventions tested

• Rehabilitation
• Chest physical therapy

Conditions studied

• Pneumonia — all drugs for Pneumonia →

Sponsor

Universidade Metodista de Piracicaba

Who can join

Adults 1 to 8, any sex, with Pneumonia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The children's susceptibility to respiratory problems is due to their anatomical and physiological characteristics; therefore, children with more severe clinical conditions may undergo invasive mechanical ventilation (IMV). However, its prolonged use favors tracheal injury, barotrauma and / or volutrauma, decreased cardiac output and oxygen toxicity, and especially the accumulation of respiratory secretions due to ineffective cough due to non-closure of the glottis and damage in the transport of mucus by the presence of the tracheal tube. Thus, triggering the development of mechanical ventilation-associated pneumonia (VAP), which is defined as a pulmonary infection that arises 48 to 72 hours after endotracheal intubation and the institution of invasive mechanical ventilation. As a consequence, respiratory work is performed by IMV, reducing the work exerted by spontaneous ventilation, causing neuromuscular disorders after 5 to 7 days of IMV, changes in muscle mechanics, reducing the capacity of the diaphragm to generate force, thus contributing to changes in modulation autonomic heart rate, changes in muscular trophism, generating physical deconditioning due to weakness and, finally, an increase in the length of hospitalization and immobilism. From this perspective, early mobilization emerges as a rehabilitation mechanism to improve muscle strength and joint mobility, as well as to improve lung function and respiratory system performance, as well as improved autonomic heart rate modulation. It can facilitate the weaning of IMV, reducing hospitalization time and promoting quality of life after discharge.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.